PA GOODDOCTOR's stock price surged 12.96% during intraday trading on Wednesday, following the release of its impressive 2025 financial results and a bullish analyst report.
The company reported a significant year-on-year increase in both revenue and net profit for 2025, with earnings substantially exceeding market expectations. This strong performance, coupled with improved profit margins driven by AI initiatives and efficiency management, provided a fundamental catalyst for the sharp price appreciation.
Adding to the positive sentiment, Citigroup issued a research report affirming a "Buy" rating on the stock and setting a target price of HK$18, citing the earnings beat and the company's strengthened financial profile.
Comments